Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LAMA leads to lower moderate to severe exacerbations: high‐risk population compared with LABA (high certainty).
1 finding from 1 review
Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LAMA showed no clear difference in moderate to severe exacerbations: low‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LAMA showed no clear difference in severe exacerbations: high‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LAMA showed no clear difference in severe exacerbations: low‐risk population compared with LABA (low certainty).
1 finding from 1 review
Pneumonia: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LAMA showed no clear difference in pneumonia: high‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Pneumonia: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LAMA showed no clear difference in pneumonia: low‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in severe exacerbations: low‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Pneumonia: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in pneumonia: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Pneumonia: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in pneumonia: low‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in moderate to severe exacerbations: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in moderate to severe exacerbations: low‐risk population compared with LAMA (low certainty).
1 finding from 1 review
Severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in severe exacerbations: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Other measures of lung function: mean change from baseline in FEV1 AUC0-4h (% predicted) after tiotropium 5.0 µg · adults and children with cystic fibrosis
1 finding from 1 review
Change in baseline trough FEV1 · adults and children with cystic fibrosis
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · adults and children with cystic fibrosis
1 finding from 1 review
Participant‐reported outcomes: quality of life (measured by CFQ‐R) · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events after tiotropium 5.0 µg · adults and children with cystic fibrosis
LAMAs showed no clear difference in adverse events after tiotropium 5.0 µg compared with placebo (high certainty).
1 finding from 1 review
Pulmonary exacerbations · adults and children with cystic fibrosis
LAMAs showed no clear difference in pulmonary exacerbations: participants reporting ≥1 pulmonary… compared with placebo (moderate certainty).
1 finding from 1 review
Exacerbations (OCS) · adults with asthma not well controlled on ICS
LAMA add‐on leads to lower exacerbations requiring oral corticosteroids (OCS) compared with ICS alone (high certainty).
1 finding from 1 review
Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · adults with asthma not well controlled on ICS
1 finding from 1 review